NASDAQ : ANIK
Anika Therapeutics, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 20.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 280.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 280.37M |
| Enterprise Value | 267.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 13.38M |
| Shares Outstanding | 13.38M |
| Shares Change (YoY) | -4.23% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 4.95% |
| Owned by Institutions (%) | 81.32% |
| Float | 11.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 23.54 |
| PS Ratio | 2.32 |
| Forward PS | 2.29 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | 498.88 |
| P/OCF Ratio | 46.91 |
| PEG Ratio | 2.35 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.21 |
| EV / EBITDA | 87.90 |
| EV / EBIT | n/a |
| EV / FCF | 475.46 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.48 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 8.31 |
| Debt / FCF | 44.93 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -2.19% |
| Return on Assets (ROA) | -0.87% |
| Return on Invested Capital (ROIC) | -2.14% |
| Return on Capital Employed (ROCE) | -1.61% |
| Weighted Average Cost of Capital (WACC) | 4.93% |
| Revenue Per Employee | $513,421 |
| Profits Per Employee | -$16,102 |
| Employee Count | 235 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.01 |
Taxes
| Measure | Value |
|---|
| Income Tax | 208,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +116.43% |
| 50-Day Moving Average | 20.66 |
| 200-Day Moving Average | 16.08 |
| Relative Strength Index (RSI) | 53.14 |
| Average Volume (20 Days) | 108,025 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 365,717 |
| Short Previous Month | 367,155 |
| Short % of Shares Out | 2.73% |
| Short % of Float | 3.24% |
| Short Ratio (days to cover) | 3.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 120.65M |
| Gross Profit | 75.00M |
| Operating Income | -2.59M |
| Pretax Income | -2.91M |
| Net Income | -3.78M |
| EBITDA | 3.04M |
| EBIT | -2.59M |
| Loss Per Share | -$0.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 38.41M |
| Total Debt | 25.25M |
| Net Cash | 13.16M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 137.28M |
| Book Value Per Share | 10.26 |
| Working Capital | 77.04M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 5.98M |
| Capital Expenditures | -5.42M |
| Depreciation & Amortization | 5.63M |
| Net Borrowing | n/a |
| Free Cash Flow | 562,000 |
| FCF Per Share | $0.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | 62.16% |
| Operating Margin | -2.15% |
| Pretax Margin | -2.41% |
| Profit Margin | -3.14% |
| EBITDA Margin | 2.52% |
| EBIT Margin | -2.15% |
| FCF Margin | 0.47% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 4.23% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.32% |
| FCF Yield | 0.20% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.00 |
| Price Target Difference | 9.79% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 6.55% |
| EPS Growth Forecast (3Y) | 118.66% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.62 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |